Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 6, 2016, Pages 1719-1722.e1

  Wang, Hsiao Han ^a,b   Li, Yu Chuan ^a   Huang, Yu Chen ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB; ANTIALLERGIC AGENT;

ARTICLE; ATOPIC DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTI-ALLERGIC AGENTS; DERMATITIS, ATOPIC; HUMANS; OMALIZUMAB; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84995436681     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.05.038     Document Type: Article

References (17)

1. 1 Makris, M.P., Papadavid, E., Zuberbier, T., The use of biologicals in cutaneous allergies—present and future. Curr Opin Allergy Clin Immunol 14 (2014), 409–416.
2. 2 Krathen, R.A., Hsu, S., Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53 (2005), 338–340.
3. 3 Lane, J.E., Cheyney, J.M., Lane, T.N., Kent, D.E., Cohen, D.J., Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54 (2006), 68–72.
4. 4 Vigo, P.G., Girgis, K.R., Pfuetze, B.L., Critchlow, M.E., Fisher, J., Hussain, I., Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55 (2006), 168–170.
5. 5 Sheinkopf, L.E., Rafi, A.W., Do, L.T., Katz, R.M., Klaustermeyer, W.B., Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29 (2008), 530–537.
6. 6 Heil, P.M., Maurer, D., Klein, B., Hultsch, T., Stingl, G., Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course—a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 8 (2010), 990–998.
7. 7 Iyengar, S.R., Hoyte, E.G., Loza, A., Bonaccorso, S., Chiang, D., Umetsu, D.T., et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 162 (2013), 89–93.
8. 8 Hotze, M., Baurecht, H., Rodriguez, E., Chapman-Rothe, N., Ollert, M., Fölster-Holst, R., et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 69 (2014), 132–135.
9. 9 Kornmann, O., Watz, H., Fuhr, R., Krug, N., Erpenbeck, V.J., Kaiser, G., Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table. Pulm Pharmacol Ther 28 (2014), 149–153.
10. Belloni, B., Ziai, M., Lim, A., Lemercier, B., Sbornik, M., Weidinger, S., et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120 (2007), 1223–1225.
11. Amrol, D., Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. South Med J 103 (2010), 554–558.
12. Ramirez del Pozo, M.E., Contreras Contreras, E., López Tiro, J., Gómez Vera, J., Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol 21 (2011), 416–417.
13. Thaiwat, S., Sangasapaviliya, A., Omalizumab treatment in severe adult atopic dermatitis. Asian Pac J Allergy Immunol 29 (2011), 357–360.
14. Kim, D.H., Park, K.Y., Kim, B.J., Kim, M.N., Mun, S.K., Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 38 (2013), 496–500.
15. Fernandez-Anton Martinez, M.C., Leis-Dosil, V., Alfageme-Roldan, F., Paravisini, A., Sánchez-Ramón, S., Suárez Fernández, R., Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr 103 (2012), 624–628.
16. Lacombe Barrios, J., Begin, P., Paradis, L., Hatami, A., Paradis, J., Des Roches, A., Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. J Am Acad Dermatol 69 (2013), 832–834.
17. Romano, C., Sellitto, A., De Fanis, U., Balestrieri, A., Savoia, A., Abbadessa, S., et al. Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. Clin Drug Investig 35 (2015), 159–168.